CHRS
Coherus Oncology, Inc.
Key Financials
Net Income
$168.0M
↑ 489.4%
Revenue
$123.9M
↑ 10.9%
Gross Profit
$116.1M
↑ 10.3%
Total Assets
$258.3M
↓ 42.4%
Operating Income
$-181134000
↓ 62.2%
Total Liabilities
$197.3M
↓ 66.0%
EPS (Diluted)
$1.43
↑ 472.0%
Long-term Debt
$73.7M
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 8/28/2026 | View on SEC |
| 424B5 | 8/28/2026 | View on SEC |
| 424B3 | 8/28/2026 | View on SEC |
| 8-K | 8/17/2026 | View on SEC |
| 8-K | 8/17/2026 | View on SEC |
| S-8 | 8/5/2026 | View on SEC |
| 10-Q | 8/5/2026 | View on SEC |
| 8-K | 8/5/2026 | View on SEC |
| SCHEDULE 13G | 7/27/2026 | View on SEC |
| 8-K | 6/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CHRS |
| Company Name | Coherus Oncology, Inc. |
| CIK | 1512762 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (650) 649-3530 |